RxDoctor Payments Data

Francis Walsh, MD

Internal Medicine · Cos Cob, CTNPI 1124174347

Payments from drug & device makers

$15,361in general payments, 2019–2025

Across 842 payments — averaging $18.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$5K
  • AstraZeneca$2K
  • GSK$1K
  • Pfizer$768
  • Merck$576
  • Bayer$498
  • plus $6K from 54 others

What the payments were for

  • Speaking & faculty fees$240%
  • Food & beverage$15,19199%
  • Education$1111%
  • Gifts$360%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)241$4,644
AstraZeneca90$1,508
GSK48$1,060
Pfizer41$768
Merck30$576
Bayer18$498
Eisai Inc.48$415
Astellas Pharma US Inc21$395
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC24$375
Acadia Pharmaceuticals Inc17$329
Exact Sciences11$313
Nestle Healthcare Nutrition Inc.19$306
Amarin Pharma, Inc.19$305
Boehringer Ingelheim13$278
Novartis15$264
Kowa Pharmaceuticals America, Inc.18$257
Amgen(2 entities)12$255
Novo Nordisk11$218
Ironwood Pharmaceuticals, Inc12$210
Johnson & Johnson(2 entities)12$206
Takeda Pharmaceuticals U.S.A., Inc.17$204
Otsuka America Pharmaceutical, Inc.8$177
Bausch Health US, LLC9$165
Scilex Pharmaceuticals Inc.9$150
Sunovion Pharmaceuticals Inc.9$147
Biohaven Pharmaceuticals, Inc.5$91
Lilly USA, LLC4$77
Genentech USA, Inc.4$75
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)3$71
Supernus Pharmaceuticals, Inc.3$69
Biogen3$60
Biohaven Pharmaceutical Holding Company Ltd.3$57
Mylan Specialty L.p.3$56
Sumitomo Pharma America, Inc.3$53
Teva Pharmaceuticals USA, Inc.3$49
Hikma Pharmaceuticals USA3$48
Amneal Pharmaceuticals LLC2$45
Lundbeck LLC2$44
Endo Pharmaceuticals Inc.3$43
Sanofi Pasteur Inc.2$37
Ascend Therapeutics US, LLC2$36
Abbott2$36
Mission Pharmacal Company2$29
Axsome Therapeutics, Inc.1$28
Actelion Pharmaceuticals US, Inc.1$26
Acorda Therapeutics, Inc1$24
Idorsia Pharmaceuticals US Inc1$24
Optinose US, Inc.1$24
Jazz Pharmaceuticals Inc.1$22
Intra-sana Laboratories1$22
Zyla Life Sciences, Inc.1$20
E.r. Squibb & Sons, L.L.C.1$20
Sanofi1$19
IBSA Pharma Inc.1$19
Almatica Pharma LLC1$19
Romark Laboratories, LC1$17
Medtronic1$17
Avanir Pharmaceuticals, Inc.1$17
Incyte Corporation1$17
Adlon Therapeutics L.p.1$16

How this compares

$15,361 in reported general payments places this provider in the 95th percentile of 2,067 internal medicine providers in Connecticut.

See all internal medicine providers in Connecticut

Medicare billing

Part B allowed, 2024
$443,886
Medicare patients
642
Services billed
7,461

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban731$192,984
OzempicSemaglutide105$120,710
XifaxanRifaximin15$42,726
JanuviaSitagliptin Phosphate84$41,089
JanumetSitagliptin Phos/Metformin Hcl76$30,528
FarxigaDapagliflozin Propanediol90$29,592
MyrbetriqMirabegron109$26,339
XareltoRivaroxaban102$26,059
LinzessLinaclotide34$21,040
JardianceEmpagliflozin70$20,345
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$19,505
MounjaroTirzepatide17$17,623
TradjentaLinagliptin79$15,160
TrulicityDulaglutide16$14,351
GemtesaVibegron36$14,201

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$768$192,984731 claims
Novo NordiskOzempic$218$120,710105 claims
MerckJanuvia, Janumet$576$71,618160 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$375$42,72615 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$1,060$40,62873 claims
Johnson & JohnsonXarelto, Invokana$206$39,599115 claims
Boehringer IngelheimJardiance, Tradjenta$278$35,506149 claims
Lilly USA, LLCMounjaro, Trulicity$77$31,97533 claims
AstraZenecaFarxiga$1,508$29,59290 claims
AbbVieLinzess, Synthroid$4,644$27,57194 claims
Astellas Pharma US IncMyrbetriq$395$26,339109 claims
Sumitomo Pharma America, Inc.Gemtesa$53$14,20136 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,067 internal medicine providers in Connecticut.

Other internal medicine in Cos Cob

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →